PTC Therapeutics | PTCT - Cost Of Sales


PTC Therapeutics reported $39.61M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amgen USD 1.6B 187M Mar/2026
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Cytokinetics USD 160K 104.24M Mar/2026
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Gilead Sciences USD 1.44B 174M Mar/2026
Incyte USD 104.5M 16.68M Mar/2026
Ionis Pharmaceuticals USD 3M 5M Mar/2026
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Novartis USD 3.46B 83M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
TG Therapeutics USD 33.51M 4.63M Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026
Xencor USD 61.66M 50.95M Jun/2025